Skip to main content
CELU
NASDAQ Life Sciences

Major Investor Discloses 20.1% Potential Stake from Convertible Notes and Warrants

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Neutral
Importance info
8
Price
$1.22
Mkt Cap
$35.182M
52W Low
$1.01
52W High
$4.35
Market data snapshot near publication time

summarizeSummary

An amendment to a Schedule 13D reveals that the Philip & Daniele Barach Family Trust now beneficially owns 20.1% of Celularity Inc.'s Class A Common Stock, primarily due to convertible notes and warrants becoming exercisable within 60 days.


check_boxKey Events

  • Increased Beneficial Ownership

    The Philip & Daniele Barach Family Trust and related individuals now beneficially own 7,558,665 shares, representing 20.1% of the Class A Common Stock.

  • Warrants Become Exercisable

    The increase in reported beneficial ownership is primarily due to 4,546,617 shares from warrants becoming exercisable within 60 days, starting June 19, 2026.

  • Source of Funds

    The beneficial ownership stems from a $10 million financing package in December 2025, consisting of senior secured and convertible promissory notes, along with associated warrants.


auto_awesomeAnalysis

This Schedule 13D/A updates the beneficial ownership of the Philip & Daniele Barach Family Trust and related individuals to 20.1% of Celularity Inc.'s Class A Common Stock. This amendment follows the original Schedule 13D filed on April 3, 2026. The significant increase in reported ownership is primarily due to 4,546,617 shares from warrants, issued as part of a $10 million financing in December 2025, now becoming exercisable within 60 days. While the original financing provided critical capital to the company, the impending exercisability of these derivatives creates a notable overhang and potential for substantial dilution for existing shareholders.

At the time of this filing, CELU was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.2M. The 52-week trading range was $1.01 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CELU - Latest Insights

CELU
Apr 22, 2026, 10:16 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CELU
Apr 21, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
9
CELU
Apr 03, 2026, 11:08 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
CELU
Mar 10, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
CELU
Mar 05, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
CELU
Jan 21, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
CELU
Jan 08, 2026, 6:15 AM EST
Filing Type: 424B3
Importance Score:
9